Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Camrelizumab (SHR-1210) in Advanced Solid Tumors
NCT02721589Phase 1Completed
- Sponsor
- Hengrui
- Start
- Apr 2016
- Primary completion
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of camrelizumab in solid tumor (advanced stage) (4 cohorts), sponsored by Hengrui. Primary endpoints: Number of Participants Experiencing Adverse Events and Number of Participants Experiencing Severe AEs. Started Apr 2016; status: completed.
02
Drugs
camrelizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02721589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721589.